AMD biology and clinical staging

Pathophysiology and Molecular Genetics of AMD

Age-related macular degeneration (AMD) is the principal cause of irreversible central visual impairment among individuals aged 50 years and older in European and developed countries. AMD represents a chronic, progressive, multifactorial degenerative disorder of the central macula, involving a complex interplay between aging, environmental exposures (especially cigarette smoking, which confers a 2- to 4-fold elevated risk), oxidative damage, and powerful genetic susceptibilities.

Molecular Genetics and Complement Cascade Dysregulation

Genome-wide association studies (GWAS) have established that chronic, low-grade inflammatory injury mediated by dysregulation of the alternative complement cascade represents a central molecular engine of AMD pathogenesis:

1. Complement Factor H (CFH) on Chromosome 1q31: Pathogenic single-nucleotide polymorphisms in the CFH gene, most notably the rs1061170 variant encoding a Tyrosine-to-Histidine substitution at codon 402 (Y402H) in exon 9, account for 35% to 50% of the population-attributable risk of AMD. Complement Factor H serves as the primary soluble fluid-phase negative regulator of the alternative complement pathway. Defective CFH fails to bind to polyanions (heparan sulfate and sialic acid) on the apical surface of the retinal pigment epithelium (RPE) and Bruch membrane. Consequently, the alternative pathway $C3$ convertase ($C3bBb$) escapes down-regulation, triggering uncontrolled, persistent complement turnover and deposition of complement activation fragments ($C3a$, $C5a$) and the terminal Membrane Attack Complex ($C5b-9$) in the sub-RPE space and choriocapillaris.
2. ARMS2 / HTRA1 Locus on Chromosome 10q26: The age-related maculopathy susceptibility 2 (ARMS2) and high-temperature requirement A serine peptidase 1 (HTRA1) gene cluster represents the second major genetic susceptibility locus. Pathogenic variants (e.g., ARMS2 A69S and HTRA1 promoter variant rs11200638) promote extracellular matrix degradation, mitochondrial dysfunction, and accelerated progression to both advanced geographic atrophy and aggressive Type 3 neovascularisation.
3. Other Complement Genes: Activating variants in Complement Component 3 (C3), Complement Factor B (CFB), and Complement Component 2 (C2) further shift the homeostatic equilibrium toward sustained alternative pathway complement hyperactivation.

Cellular Pathophysiology: RPE Senescence, Lipofuscin & Bruch Membrane

Under physiological conditions, each RPE cell must phagocytose and degrade approximately 30,000 shed rod and cone photoreceptor outer segment discs per day:

• Lipofuscin and A2E Accumulation: Decades of metabolic turnover lead to incomplete lysosomal enzyme hydrolysis of outer segment polyunsaturated fatty acids and retinoids. This produces progressive intracellular accumulation of autofluorescent granules known as lipofuscin. The principal toxic fluorophore within lipofuscin is $A2E$ (N-retinylidene-N-retinylethanolamine), a hydrophobic pyridinium bisretinoid. Upon exposure to blue and ultraviolet light ($400-480\,\text{nm}$), $A2E$ undergoes photo-oxidation, generating reactive oxygen species (ROS), singlet oxygen, and lipid hydroperoxides. These oxidants destabilize lysosomal membranes, inactivate the RPE lysosomal proton pump ($V\text{-type } H^+\text{-ATPase}$), disrupt cellular mitochondrial integrity, and trigger apoptosis of RPE cells.
• Bruch Membrane Thickening and Lipid Wall: Bruch membrane is a specialized 2 to 4 $\mu\text{m}$ thick, five-layered extracellular matrix located between the RPE and choriocapillaris (comprising the RPE basement membrane, inner collagenous layer, middle elastic layer, outer collagenous layer, and choriocapillaris basement membrane). With advancing age, Bruch membrane undergoes progressive collagen cross-linking, elastin fragmentation, calcification, and marked interstitial accumulation of neutral lipids, esterified cholesterol, and apolipoproteins ($apoB$, $apoE$). This creates a hydrophobic "lipid wall" that significantly increases hydraulic resistance, impeding the passive fluid exchange, oxygen delivery, and nutrient diffusion from the choriocapillaris to the overlying photoreceptors.

Standardized AREDS Clinical Classification of AMD

The Age-Related Eye Disease Study (AREDS) established the international clinical framework for grading AMD based on stereoscopic fundus photography:

The AREDS and AREDS2 Nutritional Supplement Formulations

The landmark AREDS trial demonstrated that a high-dose antioxidant and mineral cocktail reduced the 5-year risk of progression from intermediate AMD (Category 3) or unilateral advanced AMD (Category 4) to advanced AMD by $25\%$ (risk ratio $0.72$), and reduced the risk of moderate visual acuity loss ($\ge 15$ letters) by $19\%$.

• Original AREDS Formulation: Vitamin C ($500\,\text{mg}$), Vitamin E ($400\,\text{IU}$), Beta-carotene ($15\,\text{mg}$), Zinc ($80\,\text{mg}$ as zinc oxide), and Copper ($2\,\text{mg}$ as cupric oxide, added to prevent zinc-induced copper deficiency microcytic anaemia).
• The AREDS2 Modifications: Extensive post-hoc epidemiologic analysis of the original AREDS trial and large cancer trials (ATBC and CARET) revealed that beta-carotene significantly elevated the incidence of fatal and non-fatal lung carcinoma among current and former smokers (relative risk ~2.0). Consequently, the AREDS2 trial tested the replacement of beta-carotene with the macular xanthophyll carotenoids Lutein ($10\,\text{mg}$) and Zeaxanthin ($2\,\text{mg}$), alongside testing the addition of omega-3 long-chain polyunsaturated fatty acids (DHA $350\,\text{mg}$ + EPA $650\,\text{mg}$):
  • Lutein and zeaxanthin proved equal or superior in efficacy to beta-carotene without inducing any oncogenic risk in smokers.
  • Omega-3 fatty acids provided no additional clinical protection.
  • Zinc dosage could be safely reduced from $80\,\text{mg}$ to $25\,\text{mg}$ without diminishing therapeutic efficacy.
  • Current Standard Clinical Practice: The AREDS2 formulation containing lutein ($10\,\text{mg}$) and zeaxanthin ($2\,\text{mg}$) with zero beta-carotene is recommended for all patients with intermediate AMD in at least one eye, regardless of smoking history.